Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.67 |
| ▸ | CA2 | P00918 | 14/20 | 0.67 |
| ▸ | CA7 | P43166 | 3/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9795960 | 0.81 | CA2 (1.00) | CA1CA2CA7CA4CA9 | |
| SCHEMBL6848692 | 0.79 | KMT2A (0.70) | CA1CA2CA7CA4LMNA | |
| SCHEMBL17318656 | 0.77 | APOBEC3G (0.58) | P2RX1LMNAMEN1KMT2A | |
| SCHEMBL22118515 | 0.75 | CA2 (0.49) | CA1CA2CA7CA9CA12 | |
| SCHEMBL31669014 | 0.75 | CA2 (0.49) | CA1CA2CA7CA9CA12 | |
| SCHEMBL13739962 | 0.74 | CA2 (0.74) | CA1CA2CA7CA4CA9 | |
| SCHEMBL14372366 | 0.74 | CA1 (0.76) | CA1CA2CA9CA12PTGS1 | |
| SCHEMBL14316971 | 0.74 | CA1 (0.78) | CA1CA2CA7CA4CA9 | |
| SCHEMBL3974838 | 0.74 | CA1 (0.78) | CA1CA2CA7CA4CA9 | |
| SCHEMBL6850255 | 0.74 | CA1 (0.69) | CA1CA2CA7CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213047-A1 | CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION | PURDUE RESEARCH FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213047-A1 | CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION | CA4, CA7, CA9 | CA1 11/4885CA2 6/4885CA7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.